12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VS-5584: Phase I started

Verastem began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-daily oral VS-5584 given on days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each 21-day cycle in...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >